EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Acute Lymphopenia and Recovery With Prophylactic Pelvic Nodal Radiotherapy in Oligometastatic Prostate Cancer: Interim Results From the Prospective PROLONG2 Cohort

Xin Qi iD, Hewei Wang iD, Huan Zhang, Xueying Ren, Mingwei Ma, Xiaoying Li, Wanqi Zhang, Zhisong He, Yi Song iD, Cheng Shen, Wei Yu, Yu Fan iD und 2 weitere

Cancer Medicine · 2026-11 · 15 (11)

DOI: 10.1002/cam4.72466 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 02.11.2026. Verfasst von Xin Qi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Lymphopenia, Lymphatic Irradiation. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: 2023 National Science and Technology Major Programme for Cancer, Cardiovascular, Respiratory and Metabolic Disease Prevention and Treatment Research, Beijing WeiKang Public Welfare Foundation, Capital Health Development Research Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prophylactic pelvic nodal radiotherapy (PRT) aims to eradicate occult pelvic nodal disease in oligometastatic prostate cancer but increases lymphocyte exposure. Its early hematologic safety and lymphocyte recovery when added to radiotherapy to the prostate/prostate region and all imaging‐visible metastases remain uncertain.

Methods

PROLONG2 is an ongoing, single‐center, prospective, nonrandomized, two‐arm cohort study. This interim analysis included 133 patients who completed radiotherapy: 86 with PRT and 47 without PRT (NPRT). The key safety endpoint was acute grade ≥ 3 lymphopenia. Other assessments included lymphocyte status at 6–12 months and acute hematologic and genitourinary/gastrointestinal toxicities. The association was estimated by multivariable logistic regression adjusted for age, clinical N stage, and hormone‐sensitivity status. Survival analysis was exploratory.

Results

Acute grade ≥ 3 lymphopenia occurred in 43/86 PRT patients (50.0%) and 8/47 NPRT patients (17.0%). PRT remained associated with acute grade ≥ 3 lymphopenia after adjustment (OR, 4.03; 95% CI, 1.55–11.54; p = 0.006). At 6–12 months, grade ≥ 2 lymphopenia occurred in 18.2% versus 16.7%, and grade ≥ 3 lymphopenia in 1.3% versus 2.4%, respectively. Among evaluable PRT patients with acute grade ≥ 3 lymphopenia, 25/38 (65.8%) recovered to grade 0–1. No acute grade ≥ 3 genitourinary/gastrointestinal toxicity occurred. Progression‐free survival data remained immature, with only eight events reported.

Conclusions

PRT was associated with markedly more acute lymphopenia, but persistent severe lymphopenia was uncommon and the between‐group difference was substantially attenuated at 6–12 months. Continued prospective hematologic surveillance and mature survival data are needed to determine PRT's benefit–risk profile. Trial Registration Chinese Clinical Trial Registry: ChiCTR2400083776

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsLymphopeniaLymphatic IrradiationHumansMaleProspective StudiesAgedMiddle AgedLymphatic MetastasisPelvis

Stichwörter der Autor:innen

lymphopeniaoligometastatic prostate cancerpelvic nodal radiotherapyprogression‐free survivalradiotherapysafety

Autor:innen und Institutionen

  • Department of Radiation Oncology, Peking University First Hospital, Beijing, China.
  • Department of Urology, Peking University First Hospital, Beijing, China.

ORCID-Profile: Xin Qi, Hewei Wang, Yi Song, Yu Fan, Xianshu Gao, Hongzhen Li

Förderung

  • 2023 National Science and Technology Major Programme for Cancer, Cardiovascular, Respiratory and Metabolic Disease Prevention and Treatment Research
  • Beijing WeiKang Public Welfare Foundation
  • Capital Health Development Research Programme
  • National High Level Hospital Clinical Research Funding
  • Peking University-Golden Resource "Tengyun Clinical Research Program"

Zitieren

APA

Qi, X., Wang, H., Zhang, H., Ren, X., Ma, M., Li, X., Zhang, W., He, Z., Song, Y., Shen, C., Yu, W., Fan, Y., Gao, X., & Li, H. (2026). Acute Lymphopenia and Recovery With Prophylactic Pelvic Nodal Radiotherapy in Oligometastatic Prostate Cancer: Interim Results From the Prospective PROLONG2 Cohort. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72466

Vancouver

Qi X, Wang H, Zhang H, Ren X, Ma M, Li X, et al. Acute Lymphopenia and Recovery With Prophylactic Pelvic Nodal Radiotherapy in Oligometastatic Prostate Cancer: Interim Results From the Prospective PROLONG2 Cohort. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72466

BibTeX
@article{Qi2026,
  author = {Qi, Xin and Wang, Hewei and Zhang, Huan and Ren, Xueying and Ma, Mingwei and Li, Xiaoying and Zhang, Wanqi and He, Zhisong and Song, Yi and Shen, Cheng and Yu, Wei and Fan, Yu and Gao, Xianshu and Li, Hongzhen},
  title = {Acute Lymphopenia and Recovery With Prophylactic Pelvic Nodal Radiotherapy in Oligometastatic Prostate Cancer: Interim Results From the Prospective PROLONG2 Cohort},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/cam4.72466}
}
Kostenlos starten →